109451
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
关于维奈克拉联合表观遗传学药物治疗 T 细胞急性淋巴细胞白血病的临床前及病例系列研究
Authors Zheng B, Fu J, Wang Y, Wu J, Wang J, Li H
Received 18 February 2025
Accepted for publication 8 September 2025
Published 29 October 2025 Volume 2025:17 Pages 2513—2521
DOI https://doi.org/10.2147/CMAR.S523414
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Antonella D'Anneo
Boyue Zheng,1,* Jiyi Fu,1,* Yijing Wang,2 Jiafei Wu,1 Jun Wang,3 Hui Li1,4
1School of Medicine, University of Electronic Science and Technology of China, Chengdu, People’s Republic of China; 2Department of Hematology, Chengdu Fifth People’s Hospital, Chengdu, People’s Republic of China; 3Department of Hematology, Chengdu Second People’s Hospital, Chengdu, People’s Republic of China; 4Department of Hematology, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Hui Li, Email lihui606606@163.com
Abstract: Adult T-cell acute lymphoblastic leukemia (T-ALL) exhibits a dismal prognosis characterized by low remission rates, high relapse rates, and poor tolerance to conventional chemotherapy. The urgent development of novel therapeutic strategies is imperative to improve clinical outcomes. In this study, we propose a dual epigenetic targeting regimen combining Venetoclax with Chidamide and Azacitidine. Preclinical investigations demonstrated synergistic anti-proliferative effects of this triple-drug combination against Jurkat cells in vitro. Additionally, we retrospectively analyzed clinical data from five high-risk T-ALL patients to evaluate the regimen’s efficacy and safety. Among the cohort (all male; median age 55 years, range 25– 72), one patient had refractory T-ALL (R-TALL) following VDCP regimen induction failure, while four were newly diagnosed (ND-TALL). After one treatment cycle, four patients achieved complete remission (CR) or CR with incomplete hematologic recovery (CRi), with one additional patient attaining CR after the second cycle. Four patients achieved deep molecular remission (MRD-negative status) within two cycles, while two successfully underwent allogeneic hematopoietic stem cell transplantation (HSCT) during sustained remission. Myelosuppression emerged as the predominant treatment-related adverse event. These preclinical and clinical findings collectively support the therapeutic potential of the Combination of Venetoclax with Epigenetic Drugs as a promising option for high-risk T-ALL patients.
Keywords: acute T-lymphoblastic leukemia, epigenetics, chidamide, venetoclax, efficacy, safety
1School of Medicine, University of Electronic Science and Technology of China, Chengdu, People’s Republic of China; 2Department of Hematology, Chengdu Fifth People’s Hospital, Chengdu, People’s Republic of China; 3Department of Hematology, Chengdu Second People’s Hospital, Chengdu, People’s Republic of China; 4Department of Hematology, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Hui Li, Email lihui606606@163.com
Abstract: Adult T-cell acute lymphoblastic leukemia (T-ALL) exhibits a dismal prognosis characterized by low remission rates, high relapse rates, and poor tolerance to conventional chemotherapy. The urgent development of novel therapeutic strategies is imperative to improve clinical outcomes. In this study, we propose a dual epigenetic targeting regimen combining Venetoclax with Chidamide and Azacitidine. Preclinical investigations demonstrated synergistic anti-proliferative effects of this triple-drug combination against Jurkat cells in vitro. Additionally, we retrospectively analyzed clinical data from five high-risk T-ALL patients to evaluate the regimen’s efficacy and safety. Among the cohort (all male; median age 55 years, range 25– 72), one patient had refractory T-ALL (R-TALL) following VDCP regimen induction failure, while four were newly diagnosed (ND-TALL). After one treatment cycle, four patients achieved complete remission (CR) or CR with incomplete hematologic recovery (CRi), with one additional patient attaining CR after the second cycle. Four patients achieved deep molecular remission (MRD-negative status) within two cycles, while two successfully underwent allogeneic hematopoietic stem cell transplantation (HSCT) during sustained remission. Myelosuppression emerged as the predominant treatment-related adverse event. These preclinical and clinical findings collectively support the therapeutic potential of the Combination of Venetoclax with Epigenetic Drugs as a promising option for high-risk T-ALL patients.
Keywords: acute T-lymphoblastic leukemia, epigenetics, chidamide, venetoclax, efficacy, safety